Skip to content

Author

Karen Rowland Yeo

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Insights into Drug Absorption Impairment Mechanisms in Hepatic Impairment using Physiologically-based Pharmacokinetic Modelling: A Case Study with Nilotinib

Nilotinib is reported to have a reduced maximal drug concentration (Cmax) in patients with hepatic impairment (HI). Given this compound is poorly soluble, highly lipophilic and has a positive food effect, reduced absorption in HI may be due to impaired micelle-mediated solubility resulting from reduced intestinal bile...

Laura G. Al-Amiry Santos, Chara Litou, Karen Rowland Yeo · 0 citations
Review Open access Sep 2026

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and...

Karen Rowland Yeo, P. H. van der Graaf · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.